GeoPharma adds India, Nepal, Bangladesh, Sri Lanka and South Korea as new distribution channels for Mucotrol
July 21, 2008
PRNewswire reports that GeoPharma, Inc. has announced the expansion of the distribution agreement between the Company and Cura Pharmaceutical Co. (Cura). The original agreement signed between Cura and GeoPharma provided Cura the exclusive U.S. distribution rights of GeoPharma''s patented oral Mucotrol(TM) wafer, which had received FDA approval as a medical device. The recent extension of the primary agreement allows for additional partners to be secured, proliferating the acceptance of Mucotrol(TM) in other regions of the world previously unexplored. The new aspect of the agreement embraces two new regional partners and allows for the dissemination of Mucotrol(TM) in India, Nepal, Bangladesh, Sri Lanka and South Korea. Mucotrol(TM) is a concentrated oral gel wafer that was designed as a method of pain management for patients suffering from Oral Mucositis. Oral Mucositis is the formation of lesions on the inside of a patient''s mouth which commonly present themselves after undergoing chemotherapy treatments for cancer. The Mucotrol(TM) wafer forms a soothing coating on the inside of the patient''s mouth. The coating that is created dramatically reduces the sensitivity of these mouth lesions, improving the general comfort of the patient and making activities such as eating much more tolerable.